China Healthwise Holdings Limited (HKG:0348)
Hong Kong
· Delayed Price · Currency is HKD 0.0700
0.00 (0.00%)
Jun 26, 2025, 2:00 PM HKT
China Healthwise Holdings Revenue
In the year 2024, China Healthwise Holdings had annual revenue of 113.58M HKD, down -22.38%. China Healthwise Holdings had revenue of 52.64M in the half year ending December 31, 2024, a decrease of -19.98%.
Revenue
113.58M
Revenue Growth
-22.38%
P/S Ratio
0.48
Revenue / Employee
1.26M
Employees
90
Market Cap
54.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 113.58M | -32.74M | -22.38% |
| Dec 31, 2023 | 146.32M | 4.26M | 3.00% |
| Dec 31, 2022 | 142.06M | -28.02M | -16.48% |
| Dec 31, 2021 | 170.08M | 32.23M | 23.38% |
| Dec 31, 2020 | 137.85M | -6.02M | -4.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Akeso | 2.26B |